Muse Patent Expiration

Muse is a drug owned by Mylan Specialty Lp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2016. Details of Muse's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5886039 Method and composition for treating erectile dysfunction
Mar, 2016

(8 years ago)

Expired
US5474535 Dosage and inserter for treatment of erectile dysfunction
Dec, 2012

(12 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Muse is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Muse's family patents as well as insights into ongoing legal events on those patents.

Muse's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Muse's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Muse Generic API suppliers:

Alprostadil is the generic name for the brand Muse. 2 different companies have already filed for the generic of Muse, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Muse's generic

Alternative Brands for Muse

Muse which is used for treating erectile dysfunction., has several other brand drugs in the same treatment category and using the same active ingredient (Alprostadil). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bayer Hlthcare
Staxyn Used for treating erectile dysfunction.
Lilly
Cialis Used for treating erectile dysfunction and sexual dysfunction.
Metuchen Pharms
Stendra Used for treating erectile dysfunction.
Viatris
Viagra Used for treating erectile dysfunction.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Alprostadil. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Pfizer
Caverject
Caverject Impulse


Apart from brand drugs containing the same ingredient, some generics have also been filed for Alprostadil, Muse's active ingredient. Check the complete list of approved generic manufacturers for Muse





About Muse

Muse is a drug owned by Mylan Specialty Lp. It is used for treating erectile dysfunction. Muse uses Alprostadil as an active ingredient. Muse was launched by Mylan Speciality Lp in 1996.

Approval Date:

Muse was approved by FDA for market use on 19 November, 1996.

Active Ingredient:

Muse uses Alprostadil as the active ingredient. Check out other Drugs and Companies using Alprostadil ingredient

Treatment:

Muse is used for treating erectile dysfunction.

Dosage:

Muse is available in suppository form for urethral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.25MG SUPPOSITORY Discontinued URETHRAL
0.125MG SUPPOSITORY Discontinued URETHRAL
0.5MG SUPPOSITORY Discontinued URETHRAL
1MG SUPPOSITORY Discontinued URETHRAL